← feed

Is NCT03483649 results overdue?

Yes — results are overdue. Primary completion was 2017-10-29; the FDAAA-801 reporting deadline (2018-10-29) passed 2792 days ago and no results are posted on ClinicalTrials.gov.

Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX04 Versus Avastin® in Healthy Male Subjects

NCT IDNCT03483649 ↗
SponsorShanghai Henlius Biotech (INDUSTRY)
PhasePHASE1
StatusCOMPLETED
Primary completion2017-10-29 (ACTUAL)
Reporting deadline2018-10-29 (completion + 365d)
Days overdue2792
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 16f2a251d56dea5f… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03483649. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →